Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
2025-07-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
2025-07-04
Voluntary Announcement - Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-Week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
2025-07-03
Voluntary Announcement - Business Update: Third-Party Petition Filed against the Company’s U.S. Patent
2025-06-30
Nomination Committee - Terms of Reference
2025-06-27
Voluntary Announcement - Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis
2025-06-18
Voluntary Announcement - Ascletis Announces Poster Presentations on the Study Results of Oral Small Molecule GLP-1R Agonist ASC30 and Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate ASC47 at the 85th Scientific Sessions of American Diabetes
2025-06-09
Voluntary Announcement - Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
2025-06-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
2025-06-03
Inside Information - Final Judgment on Legal Proceedings Involving ASC41 and ASC43F
2025-05-30

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1